| scholarly article | Q13442814 |
| P50 | author | F. Javier Alvarez | Q67290462 |
| P2093 | author name string | Silvia Ravera | |
| Trinidad Gómez-Talegón | |||
| Susana P Monteiro | |||
| DRUID Project WP4 Partners | |||
| Johan Jacob de Gier | |||
| Trudy van der Linden | |||
| P2860 | cites work | A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions | Q34348610 |
| Which older patients are competent to drive? Approaches to office-based assessment | Q34654028 | ||
| Medicinal drugs and driving: from research to clinical practice | Q34866821 | ||
| Can patients taking opioids drive safely? A structured evidence-based review | Q35598089 | ||
| Drugs and alcohol among suspected impaired drivers in Canton de Vaud (Switzerland). | Q43520897 | ||
| Drugs and driving | Q72687130 | ||
| [Intravitreal injections: AFSSAPS guide to good practice] | Q83192315 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 920-931 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project | |
| P478 | volume | 74 |
| Q85280381 | A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines |
| Q28084637 | Assessment of cognitive safety in clinical drug development |
| Q89863698 | Benzodiazepines in the oral fluid of Spanish drivers |
| Q90469323 | CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria |
| Q90494161 | Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance - sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant) |
| Q36922145 | Driving and legal status of Spanish opioid-dependent patients. |
| Q91975618 | Driving performance and neurocognitive skills of long-term users of benzodiazepine anxiolytics and hypnotics |
| Q100406164 | Driving performance and neurocognitive skills of long-term users of sedating antidepressants |
| Q49161268 | Medicines and driving: evaluation of training and software support for patient counselling by pharmacists |
| Q38910199 | Parkinson's disease, antiparkinson medicines, and driving |
| Q49125513 | Presence of psychoactive substances in injured Belgian drivers |
| Q45071463 | Receipt of Warnings Regarding Potentially Impairing Prescription Medications and Associated Risk Perceptions in a National Sample of U.S. Drivers. |
| Q38388586 | Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study |
| Q41885104 | Roadside opioid testing of drivers using oral fluid: the case of a country with a zero tolerance law, Spain. |
| Q55093482 | The Problem of Benzodiazepine Use and Its Extent in the Driver Population: A Population-Based Registry Study. |
| Q47109422 | Use of driving-impairing medicines by a Spanish population: a population-based registry study |
Search more.